Latest Breaking News On - Radiation oncology - Page 4 : comparemela.com

AstraZeneca: India s drug regulator orders withdrawal of AstraZeneca s cancer drug due to potential adverse effects |

DCGI orders withdrawal of AstraZeneca's Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was

Abhishek shankarDepartment of radiation oncologyAstrazeneca pharma indiaDr br ambedkar institute rotary cancer hospitalDrug controller generalAstrazeneca pharma india limitedOlaparib tabletsAssistant professorRadiation oncologyInstitute rotary cancer hospital

HMC raises awareness on improving quality of life for patients with head and neck cancer

HMC raises awareness on improving quality of life for patients with head and neck cancer
thepeninsulaqatar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepeninsulaqatar.com Daily Mail and Mail on Sunday newspapers.

Ad daw ahBayt al dhiyafahAbdullah al ansariSal shafiMajid al abdullahMohammad shafiMustafa khalilLymphedema physiotherapy department at hamad medical corporationLymphedema physiotherapy departmentHamad medical corporationNeck cancerMultidisciplinary approachHamad bin khalifa medical cityChief medical officerSenior consultantCranio maxillofacial surgery

ASRT Foundation Awards International Collaborative Research Grant, Hosts 25th Corporate Roundtable Summit

ASRT Foundation Awards International Collaborative Research Grant, Hosts 25th Corporate Roundtable Summit
itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.

South carolinaUnited statesUnited kingdomNew yorkMaria dimopoulosCaitlin gillanSteven hardyRon digiaimoSiemens healthineersBarbara wrightSamantha skubishYat tsangMichelle bransonNicole harnettNahdia pirzadaFoundation collaborative research grant

Docs support drug regulator s move to withdraw Olaparib for some cancer patients

Oncologists on Thursday supported the Drug Controller General of India's (DCGI) mandate to state authorities to withdraw AstraZeneca's anticancer generic drug Olaparib over safety concerns.Olaparib is a chemotherapy drug and is used to treat .

New delhiShyam aggarwalAbhishek shankarAstrazeneca olaparibRajeev singh raghuvanshiDr br ambedkar institute rotary cancer hospitalDepartment of radiation oncologyDrug controller generalAstrazeneca pharma indiaAssistant professorRadiation oncologyInstitute rotary cancer hospitalMedical oncologySir ganga ram hospital

Docs support drug regulator s move to withdraw Olaparib for some cancer patients | MorungExpress

Docs support drug regulator s move to withdraw Olaparib for some cancer patients | MorungExpress
morungexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morungexpress.com Daily Mail and Mail on Sunday newspapers.

New delhiRajeev singh raghuvanshiAbhishek shankarShyam aggarwalAstrazeneca olaparibDr br ambedkar institute rotary cancer hospitalDepartment of radiation oncologyDrug controller generalAstrazeneca pharma indiaAssistant professorRadiation oncologyInstitute rotary cancer hospitalMedical oncologySir ganga ram hospital